Transcenta Holding announced that its HJB subsidiary in-licensed China rights to a portfolio of novel bone disease biotherapeutics from Eli Lilly. In January 2019, HJB, formerly known as Hangzhou Just Biotherapeutics, joined with MabSpace, a Suzhou mAb development company, to form Transcenta. As part of the Lilly portfolio, HJB acquired rights to blosozumab, an antibody to sclerostin being developed as an osteoporosis treatment. Lilly will receive an upfront payment in cash plus equity in Transcenta. It will also be eligible for regulatory and sales milestones, plus royalties. More details....
Stock Symbol: (NYSE:LLY)
Share this with colleagues: